ARAY · Accuray Inc · Investor Relations
One customer — 17% of revenue (the three months ended March 31, 2026)
“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively, and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”
One customer — 16% of revenue (the nine months ended March 31, 2026)
“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively, and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”
One customer — 13% of receivables (As of March 31, 2026)
“As of March 31, 2026, and June 30, 2025, the JV represented approximately 13% and 33%, respectively, of our total accounts receivable balance.”
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-10-06 16:00 UTC | 2026 Special Meeting of Stockholders | Shareholder meeting |
Recent news
| Date | Headline |
|---|---|
| 2026-09-27 |
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
MADISON, Wis., Sept. 27, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife® System. |
| 2026-09-11 |
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration |
| 2026-08-19 |
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
MADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026. Key Highlights The Company's transformation plan delivered more than $20 million of cost and margin improvement during |
| 2026-08-12 |
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
MADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance |
| 2026-08-05 |
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
MADISON, Wis., Aug. 5, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on August 19, 2026. |
| 2026-07-29 |
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
MADISON, Wis., July 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several decisive actions that will drive a significant improvement in its financial position, a fundamental |
| 2026-05-29 |
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer. |
| 2026-05-15 |
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation |
| 2026-05-06 |
Accuray Reports Fiscal 2026 Third Quarter Financial Results
MADISON, Wis., May 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2026. Key Highlights Transformation plan delivering ahead of expectations, with approximately $10 million of cost and margin improvements |
| 2026-04-22 |
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on May 6, 2026. |
| 2026-04-06 |
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. |
| 2026-02-04 |
Accuray Reports Fiscal 2026 Second Quarter Financial Results
MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and |
| 2026-01-21 |
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
MADISON, Wis. , Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on February 4, 2026 . |
| 2025-12-15 |
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy. Workforce optimization actions will affect approximately 15% of the company's employees. |
| 2025-11-05 |
Accuray Reports Fiscal 2026 First Quarter Financial Results
MADISON, Wis. , Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025 . Key Highlights On October 20, 2025 , the Company announced accelerated transformation efforts, including: Appointed Steve La Neve |
| 2025-10-31 |
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis. , Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve , the company's new Chief Executive Officer. As a material inducement to Mr. |
Past events
Source: https://investors.accuray.com/